SOAT1 and rheumatoid arthritis: Perhaps the most convincing evidence of JAK-STAT activation in RA, is the robust efficacy of JAK inhibitors to control RA-related disease activity, achieving response rates that exceed those of TNF inhibitors, the gold standard of initial RA biologic therapy (34).